CTIS2024-512493-98-00进行中（未招募）1 期
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study (Combi G-Vax) - IRST191.05
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.0 个研究点目标入组 28 人开始时间: 2024年6月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically confirmed glioblastoma, Female participants of child bearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 4 months thereafter., Patients must have recovered (grade 1 or less by CTCAE 5.0) from all the events related to previous treatments, The autologous surgical specimen needed for vaccine manufacturing must have been collected and sent to the Somatic Cell Therapy Lab of IRST IRCCS and must fulfil all the acceptance criteria prescribed by the GMP procedures, Availability of sufficient leukapheretic material for the preparation of the vaccine product, Karnofsky performance status (KPS) = 70% or performance status of 0 or 1 on the ECOG Performance Scale, Be willing and able to provide written informed consent/assent for the trial, Be = 18 years of age on day of signing informed consent, Life expectancy greater than 12 weeks, Patients must have normal organ and marrow function
排除标准
- •Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment, Other known malignant neoplastic diseases in the patient’s medical history with a disease-free interval of less than 5 years, except basal or squamous cell carcinoma of the skin and in situ carcinoma of the cervix uteri treated with radical surgery, Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment, Has known history of, or any evidence of active, non-infectious pneumonitis or interstitial lung disease, Has an active infection requiring systemic therapy, Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator, Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, Any known history of or is positivity of any serologic marker indicative of infection by Treponema pallidum, hepatitis B virus (HBsAg, HBsAb, HBcAB), hepatitis C virus (HCVAb, HCV RNA quantitative), human immunodeficiency virus (HIV), whether actual or previous. The sole positivity for antibodies against the HBsAg (i.e. with all other HBV markers negative) is indicative of previous HBV vaccination and therefore is acceptable, Has received a live vaccine within 30 days of planned start of study therapy. (Note: seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed), Patient with a diagnosis of immunodeficiency or is receiving systemic steroid therapy > 20 mg prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, Medical history of severe acute or chronic disease with poor prognosis, autoimmune disorder, immunodeficiency or organ allograft, Known history of active TB (Bacillus Tuberculosis), Previous treatment with a cancer vaccine., Known allergy or intolerability to components of vaccine, to TMZ, Severe myelosuppression, History of bleeding diathesis or coagulopathy, O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status equivocal
研究者
相似试验
进行中（未招募）
1 期
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II StudyglioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003755-15-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS28
进行中（未招募）
不适用
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized proof-of-principle” phase II study.metastatic melanomaMedDRA version: 15.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001410-41-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
1 期
Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II studycolorectal cancerMedDRA version: 20.0Level: LLTClassification code 10038029Term: Rectal adenocarcinoma stage IVSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10001172Term: Adenocarcinoma of colon stage IVSystem Organ Class: 100000004864EUCTR2015-000894-11-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS19
进行中（未招募）
1 期
Vaccination with dendritic cells pulsed with autologous tumorhomogenate in combination with HD-IL2 and immunomodulating radiotherapy in metastatic RCC: a phase II trial (RENALVax-2)metastatic renal cancerMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000556-14-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS37
进行中（未招募）
不适用
Vaccination med autologe dendritiske celler pulset med allogent tumorlysat (MelCancerVac) til behandling af patienter med avanceret eller metastatisk ikke-småcellet lungecancer - MelCancerVac_NSCLCEUCTR2006-002202-54-DKDandrit Biotech A/S50